Dr. Lynce is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Dana-Farber Cancer Institute
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-3000
Education & Training
- MedStar Health/Georgetown-Washington Hospital CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
- MedStar Health/Georgetown-Washington Hospital CenterResidency, Internal Medicine, 2008 - 2011
Certifications & Licensure
- MA State Medical License 2020 - 2025
- DC State Medical License 2008 - 2020
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease Start of enrollment: 2018 May 21
- TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer Start of enrollment: 2019 Apr 17
Publications & Presentations
PubMed
- Implantation of engineered adipocytes suppresses tumor progression in cancer models.Hai P Nguyen, Kelly An, Yusuke Ito, Bhushan N Kharbikar, Rory Sheng
Nature Biotechnology. 2025-02-04 - T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation.Nam Woo Cho, Sophia M Guldberg, Barzin Y Nabet, Jie Zeng Yu, Eun Ji Kim
Cancer Immunology Research. 2025-02-03 - 3 citationsGenerative artificial intelligence as a source of breast cancer information for patients: Proceed with caution.Ko Un Park, Stuart Lipsitz, Laura S Dominici, Filipa Lynce, Christina A Minami
Cancer. 2025-01-01
Journal Articles
- Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast CancerRita Nanda, Carla Falkson, Filipa C Lynce, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Reshma Mahtani, Tarah J Ballinger, Kathy D Miller, Brya..., JAMA Oncology
Authored Content
- Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast CancerJuly 2020
Press Mentions
- Inflammatory Breast Cancer Grant Allows Two Researchers to Test a New Tool for Diagnosing the Aggressive SubtypeMay 31st, 2022
- Dr. Lynce on FDA Approval of Atezolizumab/Nab-Paclitaxel in TNBCFebruary 11th, 2020
- Data Presented on PI3K Pathway Alterations at SABCS 2019December 10th, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: